---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-002455"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:06:45.211721+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entera Bio Q1 net loss $3.5M; cash $20.4M; EB613 Phase 3 protocol submitted to FDA

## Summary
- Net loss of $3.5M ($0.07/share) vs $2.6M in Q1 2025; R&D expenses rose to $2.3M from $1.1M.
- Cash $20.4M as of May 8, 2026, including BVF private placement proceeds; runway into Q1 2027.
- EB613 Phase 3 protocol submitted to FDA; bridging study completed for single-tablet formulation.
- EB612 hypoparathyroidism program prioritized with OPKO; IND expected late 2026.
- Geno Germano appointed Chairman in February; Steve Rubin joined Board.

## SEC filing metadata
- accession: 0001178913-26-002455
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/0001178913-26-002455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/zk2635218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-002455
- JSON: https://secwatch.observer/filing/0001178913-26-002455.json
- Plain text: https://secwatch.observer/filing/0001178913-26-002455.txt

## Source-grounded claims
- claim_id: 4cc254be77ede1f174869287cecc170d73fca36f
  claim: Entera Bio Ltd. reported financial results for three months ended March 31, 2026.
  evidence_excerpt: Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported financial results and key business updates for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326002455/0001178913-26-002455-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.